BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

...company is also working on a SARS-CoV-2 vaccine. Edesa licenses pair of mAbs from Novimmune Edesa Biotech Inc....
...receptor 4 Elizabeth S. Eaton, Staff Writer Ultomiris, ravulizumab-cwvz (ALXN1210) CYC065 Alexion Pharmaceuticals Inc. Cyclacel Pharmaceuticals Inc. University of Edinburgh Zydus Cadila Group Edesa Biotech Inc. Novimmune...
BioCentury | Jun 27, 2016
Company News

Cipher, Edesa Biotech deal

...in time for publication (see BioCentury, March 9, 2015). Cipher Pharmaceuticals Inc. (TSX:CPH;NASDAQ:CPHR), Mississauga, Ontario Edesa Biotech Inc....
Items per page:
1 - 2 of 2
BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

...company is also working on a SARS-CoV-2 vaccine. Edesa licenses pair of mAbs from Novimmune Edesa Biotech Inc....
...receptor 4 Elizabeth S. Eaton, Staff Writer Ultomiris, ravulizumab-cwvz (ALXN1210) CYC065 Alexion Pharmaceuticals Inc. Cyclacel Pharmaceuticals Inc. University of Edinburgh Zydus Cadila Group Edesa Biotech Inc. Novimmune...
BioCentury | Jun 27, 2016
Company News

Cipher, Edesa Biotech deal

...in time for publication (see BioCentury, March 9, 2015). Cipher Pharmaceuticals Inc. (TSX:CPH;NASDAQ:CPHR), Mississauga, Ontario Edesa Biotech Inc....
Items per page:
1 - 2 of 2